Alva10 Videos

The pandemic has made everyone realize the importance of diagnostics in healthcare, but 8 months into the pandemic, we still lack the diagnostics we need to best manage Covid-19. How can we incentivize the development of the diagnostics we need to find disease, determine risk, and assess immunity? What are the regulatory barriers, and how can they be overcome? Who pays for these tests? What can we learn from Covid-19 for the next pandemic?

Diagnostic tests can be well validated, accepted in guidelines, and even reimbursed, yet they still don’t impact patient care. Why? Improper use, lack of physician understanding & support, lack of inclusion in coverage policies, inability to track all contribute to losing the potential impact of critical diagnostic tools. Software that highlights & streamlines decision making and provides information at the point of care allows for more efficient precision delivery of these tools.

Precision Medicine usually connotes use of diagnostics and other tools to optimize care in oncology, but really we should be considering development and use of these tools in every disease area. We will discuss the challenges around development and commercialization of Precision Medicine diagnostics for use in stroke and autoimmune diseases.

Hannah Mamuszka & Satabhisa Mukhopadhyay PhD, MS, Chief Scientific Officer & Founder, 4D Path discuss the potential for digital pathology to supplant IHC, PCR, FISH, & NGS in oncology, dramatically reducing cost & increasing patient access.

Diagnostics for Covid

How to Get What We Need

What is the potential for

Precision Medicine Outside of Oncolocy?

Precision Diagnostics 4D Path

Is it Possible to Obviate the Need for NGS Panels in Oncology with a Digital Solution?

How can Software Enable 

Diagnostics to Impact Patient Care?

October 2019— Hannah Mamuszka, CEO, Alva10 on Rethinking the Companion Diagnostic Deal Structure to Benefit All Stakeholders

Companion Diagnostics Forum

Companion Diagnostics are Bad for Diagnostic Companies